Skip to main content
. 2018 Jul 26;11(5):1160–1170. doi: 10.1016/j.tranon.2018.07.010

Figure 1.

Figure 1

a. Scatterplot showing location of samples of high PARP and platinum sensitive and low PARP and platinum resistant in patients along the first two principal components (PC1 and PC2). Platinum sensitive and high PARP level samples are represented by black and low PARP and platinum resistant samples by purple dots.

b. Unsupervised clustering of the clinical samples shows differential expression patterns in patients with high PARP levels and platinum sensitivity compared to patients with low PARP levels and platinum resistant.